Cited 63 times in
Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2015-04-23T16:53:00Z | - |
dc.date.available | 2015-04-23T16:53:00Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101408 | - |
dc.description.abstract | Limited proven treatment options exist for patients with metastatic breast cancer (MBC) resistant to anthracycline and taxane treatment. Ixabepilone, a novel semisynthetic analog of epothilone B, has demonstrated single-agent activity in MBC resistant to anthracyclines and taxanes. In combination with capecitabine in a phase III trial (CA163-046) in this setting, ixabepilone prolonged progression-free survival and increased objective response rate relative to capecitabine (Thomas et al. J Clin Oncol 25:5210-5217, 2007). Here, we report the results of overall survival (OS), a secondary efficacy endpoint from the CA163-046 trial. Seven hundred fifty-two patients with MBC resistant to anthracyclines and taxanes were randomized to ixabepilone (40 mg/m(2) intravenously on day 1 of a 21-day cycle) plus capecitabine (2,000 mg/m(2) orally on days 1 through 14 of a 21-day cycle) or capecitabine alone (2,500 mg/m(2) on the same schedule). Patients receiving ixabepilone plus capecitabine treatment had a median survival of 12.9 months compared to 11.1 months for patients receiving capecitabine alone (HR = 0.9; 95%CI: 077-1.05; P = 0.19). This observed increase in median OS favored the combination; however, the difference was not statistically significant. Predefined subset analyses showed a clinically meaningful increase in OS in KPS 70-80 patients receiving ixabepilone plus capecitabine (HR = 0.75; 95% CI: 0.58-0.98). Ixabepilone plus capecitabine did not show a significant improvement in survival compared to capecitabine alone in patients with MBC resistant to anthracyclines and taxanes. The observed differences in survival favored the combination arm. A clinical benefit was also seen in patients in the KPS 70-80 subgroup | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 409~418 | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anthracyclines/therapeutic use* | - |
dc.subject.MESH | Antibiotics, Antineoplastic/therapeutic use* | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Asia | - |
dc.subject.MESH | Breast Neoplasms/drug therapy* | - |
dc.subject.MESH | Breast Neoplasms/mortality* | - |
dc.subject.MESH | Breast Neoplasms/secondary | - |
dc.subject.MESH | Capecitabine | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Resistance, Neoplasm* | - |
dc.subject.MESH | Epothilones/administration & dosage | - |
dc.subject.MESH | Europe | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Fluorouracil/analogs & derivatives | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | South America | - |
dc.subject.MESH | Taxoids/therapeutic use* | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tubulin Modulators/administration & dosage | - |
dc.subject.MESH | United States | - |
dc.title | Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Gabriel N. Hortobagyi | - |
dc.contributor.googleauthor | Henry L. Gomez | - |
dc.contributor.googleauthor | Rubi K. Li | - |
dc.contributor.googleauthor | Hyun-Cheol Chung | - |
dc.contributor.googleauthor | Luis E. Fein | - |
dc.contributor.googleauthor | Valorie F. Chan | - |
dc.contributor.googleauthor | Jacek Jassem | - |
dc.contributor.googleauthor | Guillermo L. Lerzo | - |
dc.contributor.googleauthor | Xavier B. Pivot | - |
dc.contributor.googleauthor | Fernando Hurtado de Mendoza | - |
dc.contributor.googleauthor | Binghe Xu | - |
dc.contributor.googleauthor | Linda T. Vahdat | - |
dc.contributor.googleauthor | Ronald A. Peck | - |
dc.contributor.googleauthor | Pralay Mukhopadhyay | - |
dc.contributor.googleauthor | Henri H. Roché | - |
dc.identifier.doi | 10.1007/s10549-010-0901-4 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00403 | - |
dc.identifier.eissn | 1573-7217 | - |
dc.identifier.pmid | 20454927 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs10549-010-0901-4 | - |
dc.subject.keyword | Epothilone | - |
dc.subject.keyword | Ixabepilone | - |
dc.subject.keyword | Metastatic breast cancer | - |
dc.subject.keyword | Overall survival | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 122 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 409 | - |
dc.citation.endPage | 418 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, Vol.122(2) : 409-418, 2010 | - |
dc.identifier.rimsid | 51036 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.